PMID- 28110280
OWN - NLM
STAT- MEDLINE
DCOM- 20170414
LR  - 20220316
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 147
IP  - 1
DP  - 2017 Jan 1
TI  - HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 
      Heterogeneity in HER2 Equivocal Breast Cancer.
PG  - 89-95
LID - 10.1093/ajcp/aqw211 [doi]
AB  - OBJECTIVES: Approximately 15% of breast cancers show equivocal human epidermal 
      growth factor receptor 2 (HER2) results on HER2 immunohistochemistry (IHC) and 
      are reflexed for fluorescence in situ hybridization (FISH). However, some cases 
      remain equivocal. In this study, we evaluated these double-equivocal cases by 
      using a novel gene protein assay (GPA), which can simultaneously assess HER2 gene 
      copy number and protein on a single slide using bright-field microscopy. METHODS: 
      GPA was performed on 42 HER2 IHC and FISH double-equivocal cases. RESULTS: GPA 
      was negative for amplification in 28 cases, equivocal in three cases, and 
      positive in 11 cases. The GPA results showed excellent concordance with either 
      repeat FISH using a chromosome 17 centromere probe or FISH using an alternative 
      probe. Furthermore, HER2 heterogeneity was identified in three of 11 GPA-positive 
      cases. CONCLUSIONS: HER2 GPA performs accurately and is very useful to determine 
      HER2 status in HER2 IHC and FISH double-equivocal breast cancer cases and 
      identify HER2 heterogeneity.
CI  - (c) American Society for Clinical Pathology, 2017. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com
FAU - Hou, Yanjun
AU  - Hou Y
AD  - From the Department of Pathology, Wexner Medical Center at The Ohio State 
      University, Columbus.
FAU - Nitta, Hiroaki
AU  - Nitta H
AD  - Ventana Medical Systems, Tucson, AZ.
FAU - Li, Zaibo
AU  - Li Z
AD  - From the Department of Pathology, Wexner Medical Center at The Ohio State 
      University, Columbus.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Gene Dosage
MH  - Genes, erbB-2/genetics
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization/*methods
MH  - Receptor, ErbB-2/*genetics
OTO - NOTNLM
OT  - Breast carcinoma
OT  - Fluorescence in situ hybridization
OT  - HER2 gene protein assay
OT  - HER2 heterogeneity
OT  - Immunohistochemistry
EDAT- 2017/01/23 06:00
MHDA- 2017/04/15 06:00
CRDT- 2017/01/23 06:00
PHST- 2017/01/23 06:00 [pubmed]
PHST- 2017/04/15 06:00 [medline]
PHST- 2017/01/23 06:00 [entrez]
AID - aqw211 [pii]
AID - 10.1093/ajcp/aqw211 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Jan 1;147(1):89-95. doi: 10.1093/ajcp/aqw211.